RT Journal Article
SR Electronic
T1 Neoadjuvant Tyrosine Kinase Inhibition in Locally-advanced Non-small Cell Lung Cancer: Two Cases and a Brief Literature Review
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 897
OP 902
DO 10.21873/anticanres.13191
VO 39
IS 2
A1 ANISH B. PARIKH
A1 LINDSAY HAMMONS
A1 JORGE E. GOMEZ
YR 2019
UL http://ar.iiarjournals.org/content/39/2/897.abstract
AB Background: Despite their remarkable efficacy in metastatic non-small cell lung cancer (NSCLC), EGFR- and ALK-targeted therapies have not been shown to confer any survival benefit in stage III disease, even in subsets of patients with driver mutations. Case Studies: Here, two patients with unresectable stage III NSCLC carrying mutations in the ALK (case 1) and EGFR (case 2) genes are presented. Treatment of the patient carrying an ALK mutation with an ALK inhibitor and the patient carrying an EGFR mutation with an EGFR inhibitor resulted in dramatic and durable responses. Conclusion: These cases demonstrated that ALK or EGFR mutation-positive stage III NSCLC patients can be treated with the corresponding inhibitors. They also highlight the urgent need for prospective data to assess their potential efficacy in order to improve patient outcomes.